Ocugen to Participate in Upcoming November Investor and Industry Conferences
Globe Newswire•29/10/2026•07:02 ET
1
Key Highlights
- ➤Ocugen (OCGN) will present its modifier gene therapy platform at two November conferences
- ➤Stifel conference presentation scheduled for November 12, 2026, in New York
- ➤Cell & Gene Leaders Live panel discussion scheduled for November 15, 2026, in London
- ➤Ocugen is advancing programs for retinitis pigmentosa, Stargardt disease, and geographic atrophy
MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in November 2026.
Stifel 2026 Healthcare Conference Location: New York, NY Date: Thursday, November 12, 2026 Time: 10:00–10:30 a.m. ET Format: Presentation Presenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen
Get started
Create a free account to read the full story.